|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Adenoma, multiple endocrine |
|
Esophagitis, erosive |
|
Gastroesophageal Reflux Disease |
|
Ulcer, duodenal |
|
Ulcer, gastric |
|
Zollinger- Ellison syndrome |
| |
|
|
SIDE EFFECTS:
|
|
agitation |
|
alopecia |
|
confusion |
|
constipation |
|
delirium |
|
depression |
|
diarrhea |
|
dizziness |
|
hallucinations |
|
headache |
|
insomnia |
|
paranoia |
|
pruritus |
|
urticaria |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
breast-feeding |
|
children |
|
elderly |
|
gastric cancer |
|
GI bleeding |
|
2-blocker*hypersensitivity#243"H2-blocker hypersensitivity |
|
hepatic disease |
|
infection |
|
phenylketonuria |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 40 mg once a day at bedtime or 20 mg two times a day.
Prophylaxis of recurrent duodenal ulcer: Oral, 20 mg at bedtime.
Gastric ulcer, benign, active-Treatment: Oral, 40 mg once a day at bedtime.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 10 mg at onset of symptoms; dose may be repeated once in twenty-four hours
Prophylaxis: Oral, 10 mg up to one hour before consuming food or beverages expected to cause symptoms
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 20 mg every six hours, the dosage being adjusted as needed and therapy continued for as long as clinically indicated. Doses up to 160 mg every six hours have been administered to some patients with severe Zollinger-Ellison syndrome.
Gastroesophageal reflux-Oral, 20 mg two times a day for up to six weeks.
Note: The recommended oral dose for esophagitis due to gastroesophageal reflux disease is 20 to 40 mg two times a day for up to twelve weeks.
[Prophylaxis of aspiration pneumonitis]-Oral, 40 mg given either the night before or the morning of surgery.
Note: For patients with severely impaired renal function (creatinine clearance less than 10 mL per minute)-Oral, 20 mg at bedtime. Depending on patient's response, the dosing interval may have to be increased to thirty-six to forty-eight hours |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Duodenal ulcer or
Gastric ulcer-Oral, initially 0.5 mg per kg of body weight a day, at bedtime or in two divided doses.
Gastroesophageal reflux disease-For children weighing more than 10 kg: Oral, 1 to 2 mg per kg of body weight a day, in two divided doses.
For children weighing less than 10 kg: Oral, 1 to 2 mg per kg per day, in three divided doses.
Note: In certain circumstances, doses may be titrated based on gastric pH. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
Duodenal ulcer-Treatment: Oral, 40 mg once a day at bedtime or 20 mg two times a day.
Prophylaxis of recurrent duodenal ulcer: Oral, 20 mg at bedtime.
Gastric ulcer, benign, active-Treatment: Oral, 40 mg once a day at bedtime.
Heartburn, acid indigestion, and sour stomach-Treatment: Oral, 10 mg at onset of symptoms; dose may be repeated once in twenty-four hours
Prophylaxis: Oral, 10 mg up to one hour before consuming food or beverages expected to cause symptoms
Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas)-Oral, 20 mg every six hours, the dosage being adjusted as needed and therapy continued for as long as clinically indicated. Doses up to 160 mg every six hours have been administered to some patients with severe Zollinger-Ellison syndrome.
Gastroesophageal reflux-Oral, 20 mg two times a day for up to six weeks.
Note: The recommended oral dose for esophagitis due to gastroesophageal reflux disease is 20 to 40 mg two times a day for up to twelve weeks.
[Prophylaxis of aspiration pneumonitis]-Oral, 40 mg given either the night before or the morning of surgery.
Note: For patients with severely impaired renal function (creatinine clearance less than 10 mL per minute)-Oral, 20 mg at bedtime. Depending on patient's response, the dosing interval may have to be increased to thirty-six to forty-eight hours |
|
|
|
|
|